CONMED (CNMD) vs PROCEPT BioRobotics (PRCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
CONMED (CNMD) has outperformed PROCEPT BioRobotics (PRCT) over the past year, losing 3.6% versus a loss of 48.3%. Over five years, PRCT leads with a -58.9% price change compared with -68.9% for CNMD. CONMED is the larger company by market cap ($1.32 billion vs $1.02 billion), about 1.3 times the size.
CONMED pays a dividend yielding 0.45%, while PROCEPT BioRobotics does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNMD | PRCT |
|---|---|---|
| Share price | $44.23 | $17.91 |
| Market cap | $1.32B | $1.02B |
| 1-day change | -0.56% | +2.28% |
| YTD return | +8.94% | -43.07% |
| 1-year return | -3.64% | -48.25% |
| 5-year return | -68.86% | -58.89% |
| P/E ratio (TTM) | 23.91 | — |
| Forward P/E | 9.25 | — |
| EPS (TTM) | $1.85 | $-1.98 |
| Dividend yield | 0.45% | 0.00% |
| Annual dividend | $0.20 | $0.00 |
| 52-week high | $53.66 | $38.11 |
| 52-week low | $31.44 | $16.67 |
| Distance from 52-week high | -17.57% | -53.00% |
| Analyst consensus | none | hold |
| Avg. price target upside | +2.87% | +25.18% |
| Average volume | 493.85K | 1.45M |
| Shares outstanding | 29.95M | 56.92M |
| Employees | 3,900 | 888 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CNMD has outperformed PRCT by 44.6 percentage points over the past year.
About CONMED
CNMD stock →CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as supporting products include powered resection instruments , fluid management, and visualization systems and the related single-use products that enable surgeons to perform minimally invasive sports medicine surgeries.
Healthcare · Medical Devices · 3,900 employees
About PROCEPT BioRobotics
PRCT stock →PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia.
Healthcare · Medical Devices · 888 employees
CNMD vs PRCT FAQ
Which is bigger, CONMED or PROCEPT BioRobotics?
CONMED (CNMD) is larger, with a market capitalization of $1.32B compared with $1.02B for PROCEPT BioRobotics (PRCT).
Which stock has performed better over the past year, CNMD or PRCT?
CNMD returned -3.64% over the past 12 months, compared with -48.25% for PRCT (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, CONMED or PROCEPT BioRobotics?
CONMED pays a dividend yielding 0.45%, while PROCEPT BioRobotics does not currently pay a regular dividend.
Are CONMED and PROCEPT BioRobotics in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.